الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 211 |  |  |
| | | from | 211 | | |
Abstract
his study included 66 patients with locally
advancedbreast cancer not operated and did not receive
any prior chemotherapy, radiotherapy or hormonal treatment
referred to El-salam oncology center from April 2010 through
October 2012.
Patients were randomly allocated into 2 groups, each
consisting of 33 patients: Group (A) patientsreceived 4 cycles
of FEC regimen (5-fluorouracil 500 mg/m2, epirubicin 100
mg/m2, cyclophosphamide 500 mg/m2) each repeated every 21
days. Group (B): patients received 4 cycles of epirubicin 60
mg/m2, docetaxel 75 mg/m2each repeated also every 21 days.
The two treatment group were comparable as regards of
patient characteristics such as age, performance, tumor grade,
histopathology, tumor size, axillary lymph node status,
hormonal status (ER - PR).
Treatment regimens in the two groups were tolerable
with no treatment related mortality. There was no significant
difference as regard treatment related toxicity between the two
treatment groups.
The 2 years disease free survival for group A and B was
statistically significant P value 0.017.
The 2 years overall survival was statistically insignificant
P value 0.064.
T
Summary
143
There was no statistically significant difference regarding
Distribution of the sites of distant metastases p value 0.815.
The response of treatment was mainlyto ERand/ orPR -ve
and Her- 2 neu -ve in both groups withno statistically significant
difference.
Multi-regression analysis shows that both LN (1-3) with
T-Size (T3) are the most sensitive predictors for increased DFS
(p<0.01).
Multi-regression analysis shows that PCR with Hormonal
status (ER&/PR -ve) & (Her 2 neu –ve), in addition to
performance status (0 & 1) are the most sensitive predictors for
increased OS (p<0.01).
In conclusion the addition of non cross resistance agent
(Docetaxel) to Epirubcin showed statistically significant
difference in 2 years DFS and no statistically significant
difference regarding 2 years OS. There was no statistically
significant difference as regards toxicity which was tolerable
for the two regimens.
Although the previous findings were recorded, but still
this study lacks the adequate number of patients and needs a
longer time of follow up.